The data was published in the New England Journal of Medicine (NEJM).
The Phase 3 STRIVE study evaluated 161 patients 12 years or older who received at least one dose of either Kalydeco as a single 150 mg tablet or placebo twice daily.
The data demonstrated improvements in lung function and other measures of disease throughout the 48week study.